How antipsychotics work—From receptors to reality
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in NeuroRX
- Vol. 3 (1) , 10-21
Abstract
How does a small molecule blocking a few receptors change a patients' passionately held paranoid belief that the FBI is out to get him? To address this central puzzle of antipsychotic action, we review a framework linking dopamine neurochemistry to psychosis, and then link this framework to the mechanism of action of antipsychotics. Normal dopamine transmission has a role in predicting novel rewards and in marking and responding to motivationally salient stimuli. Abnormal dopamine transmission alters these processes and results in an aberrant sense of novelty and inappropriate assignment of salience leading to the experience of psychosis. Antipsychotics improve psychosis by diminishing this abnormal transmission by blocking the dopamine D2/3 receptor (not D1 or D4), and although several brain regions may be involved, it is suggested that the ventral striatal regions (analog of the nucleus accumbens in animals) may have a particularly critical role. Contrary to popular belief, the antipsychotic effect is not delayed in its onset, but starts within the first few days. There is more improvement in the first 2 weeks, than in any subsequent 2-week period thereafter. However, a simple organic molecule cannot target the complex phenomenology of the individual psychotic experience. Antipsychotics diminish dopamine transmission and thereby dampen the salience of the pre-occupying symptoms. Therefore, in the initial stage of an antipsychotic response, the patients experience a detachment from symptoms, a relegation of the delusions and hallucinations to the back of their minds, rather than a complete erasure of the symptoms. Only with time, and only in some, via the mediation of new learning and plasticity, is there a complete resolution of symptoms. The implications of these findings for clinical care, animal models, future target discovery and drug development are discussed.Keywords
This publication has 161 references indexed in Scilit:
- Occupancy of Striatal and Extrastriatal Dopamine D2/D3 Receptors by Olanzapine and HaloperidolNeuropsychopharmacology, 2005
- An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and BehaviorCell, 2005
- Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceMolecular Psychiatry, 2004
- Choosing the Right Dose of Antipsychotics in SchizophreniaCNS Drugs, 2001
- A Rating Scale for Psychotic Symptoms (RSPS)Schizophrenia Research, 1999
- Effects of the D 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophreniaJournal of Neural Transmission, 1998
- Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatumJournal of Comparative Neurology, 1996
- Dopamine D4‐Like Receptor Elevation in Schizophrenia: Cloned D2 and D4 Receptors Cannot Be Discriminated by Raclopride Competition Against [3H]NemonaprideJournal of Neurochemistry, 1995
- Cortical regulation of subcortical dopamine systems and its possible relevance to schizophreniaJournal of Neural Transmission, 1993
- Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurones in ratsLife Sciences, 1988